@article{9a54ec4c8bf346cebdf0b58848f67e25,
title = "Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung",
abstract = "Stereotactic ablative radiotherapy (SABR) is a well-established treatment for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) and pulmonary oligometastases. The use of single-fraction SABR in this setting is supported by excellent local control and safety profiles which appear equivalent to multi-fraction SABR based on the available data. The resource efficiency and reduction in hospital outpatient visits associated with single-fraction SABR have been particularly advantageous during the COVID-19 pandemic. Despite the increased interest, single-fraction SABR in subgroups of patients remains controversial, including those with centrally located tumours, synchronous targets, proximity to dose-limiting organs at risk, and concomitant severe respiratory illness. This review provides an overview of the published randomised evidence evaluating single-fraction SABR in primary lung cancer and pulmonary oligometastases, the common clinical challenges faced, immunogenic effect of SABR, as well as technical and cost-utility considerations.",
keywords = "Lung cancer, Lung oligometastases, NSCLC, Radiation therapy, SABR, Single fraction",
author = "Kang, {Therese M. J.} and Nicholas Hardcastle and Singh, {Anurag K.} and Slotman, {Ben J.} and Videtic, {Gregory M. M.} and Stephans, {Kevin L.} and Felipe Cou{\~n}ago and Louie, {Alexander V.} and Matthias Guckenberger and Harden, {Susan V.} and Plumridge, {Nikki M.} and Shankar Siva",
note = "Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: NH received research grant funding from Varian Medical Systems for research into kidney SABR, and from Reflexion Medical for research into biologically guided radiation therapy. FC received sponsored research from Janssen; consulting, advisory role for AstraZeneca and Janssen; Lectures and educational activities for AstraZeneca, Astellas and Janssen; travel, accommodation, and expenses from AstraZeneca, Astellas and Janssen. AVL received honoraria from AstraZeneca for speaking engagement and advisory board. SS received grants from Varian industries, Merck-Sharp-Dohme, Bayer Pharmaceuticals; honoraria from AstraZeneca and Reflexion for speaking engagement and advisory board; grants from AstraZeneca for education activities. TMJ, AKS, BJS, GMMV, KLS, MG, SVH and NMP declare no conflict of interests. Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
month = aug,
day = "1",
doi = "10.1016/j.lungcan.2022.06.014",
language = "English",
volume = "170",
pages = "185--193",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
}